Evidence map›Paper›PMID 41952015›Full record

ReviewAAPS PharmSciTech2026

Comprehensive Modalities for Cataract Management: Preventive, Surgical, and Non-Surgical Approaches Using Conventional and Nanotechnology-Based Therapies.

Aya Hussein, Maha El-Kayal, Rehab Nabil Shamma, Asmaa F Khafaga, Nihal Farid Younes

Abstract readReview
PubMed Publisher
In one paragraph

Review in AAPS PharmSciTech, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Aya HusseinDepartment of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Future University in Egypt, 90Th St, New Cairo 3, Cairo Governorate, Cairo, 11835, Egypt.ORCID http://orcid.org/0000-0002-1176-575X
Maha El-KayalDepartment of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Future University in Egypt, 90Th St, New Cairo 3, Cairo Governorate, Cairo, 11835, Egypt. maha.osama@fue.edu.eg.ORCID http://orcid.org/0000-0002-5433-5207
Rehab Nabil ShammaDepartment of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, P.O. Box 11562, Cairo, Egypt. rehab.shamma@pharma.cu.edu.eg.ORCID http://orcid.org/0000-0002-7635-6842
Asmaa F KhafagaDepartment of Pathology, College of Veterinary Medicine, King Faisal University, Al-Ahsa 31982, Saudi Arabia.ORCID http://orcid.org/0000-0003-4235-669X
Nihal Farid YounesDepartment of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, P.O. Box 11562, Cairo, Egypt.ORCID http://orcid.org/0000-0002-5105-3669

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Among ocular diseases, cataract are globally considered the primary cause of blindness. Cataract development is mainly attributed to oxidative stress, which damages epithelial lens proteins and lipids, resulting in clouding or opacification of the normally transparent lens and altering its refractive index. The widespread prevalence of environmental and pathological factors associated with increased cataract risk has heightened interest in innovative therapeutic strategies. Addressing the limitations of current pharmaceutical and surgical interventions is crucial, and the emergence of nanomedicine offers promising opportunities for more precise and effective treatment and prevention strategies compared to conventional methods. Due to their unique properties, nanoparticles have demonstrated significant potential in targeting biological systems and modulating critical physiological processes. This review highlights the potential of various traditional and nanotechnology-based therapeutic agents, including chemical compounds, antioxidants and herbal extracts showing anti-cataract activity both in vitro and in vivo. Furthermore, it explores the benefits and challenges associated with various ocular drug delivery routes for cataract treatment and prevention.

Indexed as

CataractAnimalsAntioxidantsCataract ExtractionDrug Delivery SystemsHumansNanomedicineNanoparticlesNanotechnologyOxidative StressAntioxidantsantioxidantscataractconventional treatmentsnanotechnologypost-surgical approachessurgery

Identifiers

PMID41952015

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.